Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis

Table 4

Study name	Trial/author, year	Was randomization carried out appropriately?	Was the concealment of treatment allocation adequate?	Were the care providers, participants, and outcome assessors blind to treatment allocation?	Were the groups similar at the outset of the study in terms of prognostic factors, for example, severity of disease?	Were there any unexpected imbalances in drop-outs between groups?	Is there any evidence to suggest that the authors measured more outcomes than they reported?	Did the analysis include an intention-to-treat analysis? If so, was this appropriate and were appropriate methods used to account for missing data?
BREVACTA	Kivitz, 2014; Olech, 2013 (abstract)	Yes	Yes	Yes	Yes	No	No	Yes
TOWARD	Genovese, 2008	Unclear	Unclear	Yes	Yes	No	No	Yes
REALISTIC	Weinblatt, 2012	Yes	Yes	Yes	Yes	No	No	Yes
ROSE	Yazici, 2012	Unclear	Unclear	Yes	Yes	No	No	Yes
ACQUIRE	Genovese, 2011	Yes	Unclear	Yes	Yes	No	No	Yes
AMPLE	Weinblatt, 2013	Unclear	Unclear	No	Yes	No	No	Yes
AUGUST II	van Vollenhoven, 2011	Yes	Yes	Yes	Yes	No	No	Yes
ACT–RAY	Dougados, 2013	Yes	Yes	Yes	Yes	No	No	Yes
ADACTA	Gabay, 2013	Yes	Yes	Yes	Yes	No	No	Yes
ABT-Kremer 1	Kremer, 2003; Kremer, 2005	Yes	Yes	Yes	Yes	No	No	Unclear
ABT-Kremer 2	Kremer, 2006; Russell, 2007	Yes	Yes	Yes	Yes	No	No	Yes
ATTEST	Schiff, 2008	Yes	Unclear	Yes	Yes	No	No	Yes
ADA–Van de Putte 2	Van de Putte, 2004	Yes	Yes	Yes	Yes	No	No	Yes
ADA–Van de Putte 1	Van de Putte, 2003	Unclear	Unclear	Yes	Yes	No	No	Yes
ARMADA	Weinblatt, 2003	Yes	Yes	Yes	Yes	No	No	Yes
ADA–Keystone	Keystone, 2004	Unclear	Unclear	Yes	Yes	No	No	Yes
FAST4WARD	Fleischmann, 2009	Yes	Yes	Yes	Yes	No	No	Yes
RAPID 1	Keystone, 2008; Strand, 2009	Unclear	Unclear	Yes	Yes	No	No	Yes
RAPID 2	Smolen, 2009; Strand, 2011	Unclear	Unclear	Yes	Yes	No	No	Yes
NCT00544154	Choy, 2012	Yes	Yes	Yes	Yes	No	No	Yes
ETN–Mathias/Moreland	Moreland, 1999; Mathias, 2000	Yes	Yes	Yes	Yes	No	No	Yes
ETN–Weinblatt	Weinblatt, 1999	Yes	Yes	Yes	Yes	No	No	Unclear
ADORE	Van Riel, 2006; van Riel, 2008	Unclear	Unclear	No	Yes	No	No	Yes
ETN–Combe	Combe, 2006; Combe, 2009	Unclear	Unclear	Yes	Yes	No	No	Yes
GLB–Kay	Kay, 2008	Yes	Yes	Yes	Yes	No	No	Unclear
GO–FORWARD	Keystone, 2009; Genovese, 2012	Yes	Yes	Yes	Yes	No	No	Unclear
ATTRACT	Lipsky, 2000; Maini, 1999	Yes	Yes	Yes	Yes	No	No	Yes
START	Westhovens, 2006	Unclear	Unclear	Yes	Yes	No	No	Yes
CHARISMA	Maini, 2006	Yes	Yes	Yes	Yes	No	No	Yes
OPTION	Smolen, 2008	Yes	Yes	Yes	Yes	No	No	Yes
LITHE	Kremer, 2011; Fleischmann, 2013	Yes	Yes	Yes	Yes	No	No	Yes
ORAL-Solo (Pfizer A3921045)	Fleishmann, 2012	Yes	Yes	Yes	Yes	No	No	Yes
TOFA monotherapy (Pfizer A3921035)	Fleischmann, 2012	Unclear	Unclear	Yes	Yes	No	No	Unclear
ORAL-Standard (Pfizer A3921064)	van Vollenhoven, 2012	Yes	Yes	Unclear	Yes	No	No	Unclear
TOFA+MTX–Kremer (Pfizer A3921025)	Kremer, 2012	Unclear	Unclear	Yes	Yes	No	No	Unclear
ORAL-Scan (Pfizer A3921044)	Van der Heijde, 2013; van der Heijde, 2012; van der Heijde, 2011	Yes	Yes	Yes	Yes	No	No	Unclear